Background: Cystic echinococcosis (CE) is a disease caused by the larval stage of Echinococcus granulosus sensu lato  (s.l.). The treatment of CE mainly relies on the use of benzimidazoles, which can commonly cause adverse side effects. Therefore, more efficient treatment options are needed. Drug repurposing is a useful approach for advancing drug development. We have evaluated the in vitro protoscolicidal effects of tropisetron and granisetron in E. granulosus sensu stricto (s.s.) and assessed the expression of the calcineurin (CaN) and calmodulin (CaM) genes, both of which have been linked to cellular signaling activities and thus are potentially promising targets for the development of drugs.

Methods: Protoscoleces (PSC) of E. granulosus (s.s.) (genotype G1) obtained from sheep hepatic hydatid cysts were exposed to tropisetron and granisetron at concentrations of 50, 150 and 250 µM for various periods of time up to 10 days. Cyclosporine A (CsA) and albendazole sulfoxide were used for comparison. Changes in the morphology of PSC were investigated by light microscopy and scanning electron microscopy. Gene expression was assessed using real-time PCR at the mRNA level for E. granulosus calcineurin subunit A (Eg-CaN-A), calcineurin subunit B (Eg-CaN-B) and calmodulin (Eg-CaM) after a 24-h exposure at 50 and 250 µM, respectively.

Results: At 150 and 250 µM, tropisetron had the highest protoscolicidal effect, whereas CsA was most effective at 50 µM. Granisetron, however, was less effective than tropisetron at all three concentrations. Examination of morphological alterations revealed that the rate at which PSC were killed increased with increasing rate of PSC evagination, as observed in PSC exposed to tropisetron. Gene expression analysis revealed that tropisetron at 50 μM significantly upregulated Eg-CaN-B and Eg-CaM expression while at 250 μM it significantly downregulated both Eg-CaN-B and Eg-CaM expressions; in comparison, granisetron decreased the expression of all three genes at both concentrations.

Conclusions: Tropisetron exhibited a higher efficacy than granisetron against E. granulosus (s.s.) PSC, which is probably due to the different mechanisms of action of the two drugs. The concentration-dependent effect of tropisetron on calcineurin gene expression might reflect its dual functions, which should stimulate future research into its mechanism of action and evaluation of its potential therapeutical effect in the treatment of CE.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8042905PMC
http://dx.doi.org/10.1186/s13071-021-04691-9DOI Listing

Publication Analysis

Top Keywords

tropisetron granisetron
12
250 µm
12
gene expression
12
tropisetron
9
effects tropisetron
8
calcineurin calmodulin
8
exposed tropisetron
8
150 250
8
calcineurin subunit
8
rate psc
8

Similar Publications

Introduction: Selective 5-hydroxytryptamine 3 receptor (5-HT3) antagonists are commonly used to prevent nausea and vomiting (NV) after cesarean section, but the comparative efficacy of different 5-HT3 antagonists remains unclear. This network meta-analysis aimed to determine which 5-HT3 antagonists might be the preferred choice for preventing NV in parturient scheduled for elective cesarean delivery under spinal anesthesia.

Evidence Acquisition: PubMed, EMBASE, Cochrane library, and Web of Science were searched for relevant randomized controlled trials (RCTs) published before August 24, 2023.

View Article and Find Full Text PDF

Obsessive-compulsive disorder (OCD) is the fourth most common mental disorder, and selective serotonin reuptake inhibitors (SSRIs) are the cornerstone of its pharmacological treatment. About 40-60% of the cases are treatment-refractory, and this makes searching for second-line treatment necessary. 5-Hydroxytryptamine-3 (5-HT3) antagonists are among the many medications that have been used in augmentation with SSRIs.

View Article and Find Full Text PDF
Article Synopsis
  • A systematic review and meta-analysis were conducted to evaluate the effectiveness of serotonin 3 receptor antagonists (5-HT3R-As) in treating obsessive-compulsive disorder (OCD) by analyzing data from 10 double-blind, randomized, placebo-controlled trials involving 628 participants.
  • * The analysis showed that 5-HT3R-As significantly improved the overall OCD symptoms (measured by the Yale-Brown Obsessive Compulsive Scale), including both obsession and compulsion scores when compared to placebo.
  • * Despite these positive outcomes, there were no significant differences in treatment discontinuation or adverse event rates between 5-HT3R-As and placebo, indicating the need for further studies with larger sample sizes to confirm these findings
View Article and Find Full Text PDF

Introduction: Genetic variants may affect drug efficacy on postoperative nausea and vomiting (PONV). The understanding of these mechanisms will help to identify the surgical patients who might benefit from specific prophylactic and therapeutic antiemetic treatment. The aim of the present review was to investigate gene polymorphisms that influence 5-hydroxytryptamine (serotonin) type 3 receptor antagonists (5HT3RA) efficacy in PONV.

View Article and Find Full Text PDF
Article Synopsis
  • 5-HT receptor antagonists like ondansetron and granisetron are primarily used to treat nausea in chemotherapy patients, but they may also have potential benefits for various nervous system disorders, including addiction and anxiety.
  • Research indicates that chemotherapy can increase serotonin (5-HT) levels that contribute to pain, leading to the hypothesis that 5-HT receptor antagonists might help combat neuropathic pain caused by chemotherapy.
  • The review encourages further investigation into the role of 5-HT receptor antagonists in managing chemotherapy-induced peripheral neuropathic pain (CIPN), aiming to enhance current pain relief strategies for cancer patients.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!